A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P)

• ClinicalTrials.gov Identifier: NCT05726864
• Recruitment Status: Recruiting
• First Posted: February 14, 2023
• Last Update Posted: May 3, 2024
• Sponsor: Elicio Therapeutics
• Information provided by (Responsible Party): Elicio Therapeutics

Tracking Information

• First Submitted Date: February 3, 2023
• First Posted Date: February 14, 2023
• Last Update Posted Date: May 3, 2024
• Actual Study Start Date: April 14, 2023
• Estimated Primary Completion Date: November 2026 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 11, 2023)

• Phase 1: Evaluate the safety of ELI-002 7P [ Time Frame: 28 days after the first dose of ELI-002 7P ]
  Safety will be assessed by the incidence of adverse events (AEs) and clinically significant changes in laboratory tests and vital signs
• Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival) [ Time Frame: After the last radiographic assessment at Visit 26 (Week 150) ]
  DFS is assessed by the investigator through computed tomography (CT) imaging or magnetic resonance imaging (MRI) with contrast and using iRECIST criteria

Original Primary Outcome Measures (submitted: February 3, 2023)

• Phase 1: Evaluate the safety of ELI-002 7P [ Time Frame: 28 days after the first dose of ELI-002 7P ]
  Safety will be assessed by the incidence of adverse events (AEs) and clinically significant changes in laboratory tests and vital signs
• Phase 2: Determine whether ELI-002 7P improves relapse-free survival (RFS) compared with Observation [ Time Frame: After the last radiographic assessment at Visit 23 (Week 106) ]
  RFS is assessed by the central imaging laboratory through computed tomography (CT) imaging or magnetic resonance imaging (MRI) with contrast and using iRECIST criteria

Current Secondary Outcome Measures (submitted: October 11, 2023)

• Phase 1 and Phase 2: Determine the biomarker reduction or clearance rate [ Time Frame: 6 months ]
  The ctDNA reduction or clearance is defined as reduction or clearance of ctDNA from baseline, or if ctDNA was not detectable at baseline, serum tumor biomarker (such as CA19-9 and CEA) reduction and clearance compared to baseline
• Phase 2: Determine the 1-year DFS [ Time Frame: 1 year ]
  Compare between cohorts, ELI-002 7P vs Observation, the 1-year DFS
• Phase 2: Evaluate the safety of ELI-002 7P [ Time Frame: 30 days after the last ELI-002 7P dose ]
  Safety will be assessed by the incidence of AEs and clinically significant laboratory tests and vital signs
• Phase 2: Determine the objective response rate (ORR) in subjects who crossover from Observation to ELI-002 7P treatment after confirmed progressive disease according to iRECIST [ Time Frame: After Visit 13 (Week 20) ]
  ORR is defined as the proportion of subjects achieving a complete response or partial response per iRECIST

Original Secondary Outcome Measures (submitted: February 3, 2023)

• Phase 1 and Phase 2: Determine the biomarker reduction or clearance rate [ Time Frame: 6 months ]
  The ctDNA reduction or clearance is defined as reduction or clearance of ctDNA from baseline, or if ctDNA was not detectable at baseline, serum tumor biomarker (such as CA19-9 and CEA) reduction and clearance compared to baseline
• Phase 2: Determine the 1-year RFS [ Time Frame: 1 year ]
  Compare between cohorts, ELI-002 7P vs Observation, the 1-year RFS
• Phase 2: Evaluate the safety of ELI-002 7P [ Time Frame: 30 days after the last ELI-002 7P dose ]
  Safety will be assessed by the incidence of AEs and clinically significant laboratory tests and vital signs
• Phase 2: Determine the objective response rate (ORR) in subjects who crossover from Observation to ELI-002 7P treatment after confirmed progressive disease according to iRECIST [ Time Frame: After Visit 14 (Week 24) ]
  ORR is defined as the proportion of subjects achieving a complete response or partial response per iRECIST

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
• Official Title: First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
• Brief Summary: This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

Detailed Description

The study consists of 3 phases: Phase 1A, Phase 1B, and Phase 2. In Phase 1A, seven Amph modified KRAS and NRAS peptides, G12D, G12R, G12V, G12A, G12C, G12S, G13D (Amph-Peptides 7P) will be evaluated in combination with recommended Phase 2 dose of Amph-CpG-7909 (10.0mg). This Amph-CpG-7909 dose will be evaluated with two Amph-Peptides 7P dose levels (1.4mg and 4.9mg) in 6 subjects per dose level. Following enrollment of these 12 subjects, the independent data monitoring committee (IDMC) will decide if another 6 subjects should be enrolled or if the dose can be determined for Phase 1B and Phase 2 portions of the study to be opened. If another 6 subjects are enrolled to Phase 1A, the IDMC will meet again to decide upon the dose for Phase 1B and Phase 2 prior to opening these portions of the study.

In Phase 1B, one dose expansion cohort of up to 17 colorectal cancer [CRC] subjects may be added to evaluate for preliminary evidence of biomarker response, including circulating tumor deoxyribonucleic acid (ctDNA) and/or serum tumor biomarker (such as CA19-9 and CEA) reduction and clearance in KRAS and NRAS.

In Phase 2, an additional 135 PDAC subjects will be randomized 2:1 (ELI-002 7P versus observation) to further evaluate antitumor activity. Subjects randomized to ELI-002 7P will receive subcutaneous (SC) injections of ELI-002 7P during Immunization and Booster Periods. Subjects randomized to observation will have the same safety and efficacy evaluations and will follow the same assessment schedule as subjects randomized to ELI-002 7P but will not receive study treatment. Subjects randomized to observation will be able to elect to cross-over to ELI-002 7P treatment in the event of confirmed disease progression.

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Pancreatic Ductal Adenocarcinoma
• Colorectal Cancer
• KRAS G12D
• KRAS G12R
• KRAS G12V
• KRAS G12A
• KRAS G12C
• KRAS G12S
• KRAS G13D
• NRAS G12D
• NRAS G12R
• NRAS G12V
• NRAS G12C
• NRAS G12S

Intervention

Drug: ELI-002 7P

ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)

Study Arms

• Experimental: Phase 1A: ELI-002 7P (Low Peptide dose)
  ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
  Intervention: Drug: ELI-002 7P
• Experimental: Phase 1A: ELI-002 7P (High Peptide dose)
  ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
  Intervention: Drug: ELI-002 7P
• Experimental: Phase 1B: ELI-002 7P
  The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
  Intervention: Drug: ELI-002 7P
• Experimental: Phase 2 randomized: ELI-002 7P
  The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
  Intervention: Drug: ELI-002 7P

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: February 3, 2023): 156
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: November 2026
• Estimated Primary Completion Date: November 2026 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor
• Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable
• Screening CT is negative for recurrent disease
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

• Presence of tumor mutations where specific therapy is approved
• Known brain metastases
• Use of immunosuppressive drugs

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Clinical Trial Inquiries; 617-714-9884; clinicaltrialinquiries@elicio.com

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT05726864
• Other Study ID Numbers: ELI-002-201
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Elicio Therapeutics
• Original Responsible Party: Same as current
• Current Study Sponsor: Elicio Therapeutics
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Elicio Therapeutics
• Verification Date: May 2024